Rapid increase in circulating leptin in ventromedial hypothalamus-lesioned rats: role of hyperinsulinemia and implication
for upregulation mechanism. Diabetes October 1999 48:2034-2038; doi:10.2337/diabetes.48.10.2034
Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes October 1999 48:1899-1906; doi:10.2337/diabetes.48.10.1899
Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes October 1999 48:2028-2033; doi:10.2337/diabetes.48.10.2028
Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes October 1999 48:2066-2073; doi:10.2337/diabetes.48.10.2066
Tumor necrosis factor-alpha-238 and -308 polymorphisms do not associated with traits related to obesity and insulin resistance.
Diabetes October 1999 48:2096-2098; doi:10.2337/diabetes.48.10.2096
Mechanisms of glucose hypersensitivity in beta-cells from normoglycemic, partially pancreatectomized mice. Diabetes October 1999 48:1954-1961; doi:10.2337/diabetes.48.10.1954
Two novel immortal pancreatic beta-cell lines expressing and secreting human islet amyloid polypeptide do not spontaneously
develop islet amyloid. Diabetes October 1999 48:1962-1970; doi:10.2337/diabetes.48.10.1962
Palmitate and oleate induce the immediate-early response genes c-fos and nur-77 in the pancreatic beta-cell line INS-1. Diabetes October 1999 48:2007-2014; doi:10.2337/diabetes.48.10.2007
Acute modulation of albumin microvascular leakage by advanced glycation end products in microcirculation of diabetic rats
in vivo. Diabetes October 1999 48:2052-2058; doi:10.2337/diabetes.48.10.2052
Identification of peptides from autoantigens GAD65 and IA-2 that bind to HLA class II molecules predisposing to or protecting
from type 1 diabetes. Diabetes October 1999 48:1937-1947; doi:10.2337/diabetes.48.10.1937
Tyrosine phosphorylation of specific protein kinase C isoenzymes participates in insulin stimulation of glucose transport
in primary cultures of rat skeletal muscle. Diabetes October 1999 48:1922-1929; doi:10.2337/diabetes.48.10.1922
Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal
islet transplantation? Diabetes October 1999 48:1907-1914; doi:10.2337/diabetes.48.10.1907
Acute modulation of albumin microvascular leakage by advanced glycation end products in microcirculation of diabetic rats
in vivo. Diabetes October 1999 48:2052-2058; doi:10.2337/diabetes.48.10.2052
Tyrosine phosphorylation of specific protein kinase C isoenzymes participates in insulin stimulation of glucose transport
in primary cultures of rat skeletal muscle. Diabetes October 1999 48:1922-1929; doi:10.2337/diabetes.48.10.1922
Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal
islet transplantation? Diabetes October 1999 48:1907-1914; doi:10.2337/diabetes.48.10.1907
Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal
islet transplantation? Diabetes October 1999 48:1907-1914; doi:10.2337/diabetes.48.10.1907
Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal
islet transplantation? Diabetes October 1999 48:1907-1914; doi:10.2337/diabetes.48.10.1907
Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal
islet transplantation? Diabetes October 1999 48:1907-1914; doi:10.2337/diabetes.48.10.1907
Palmitate and oleate induce the immediate-early response genes c-fos and nur-77 in the pancreatic beta-cell line INS-1. Diabetes October 1999 48:2007-2014; doi:10.2337/diabetes.48.10.2007
Identification of peptides from autoantigens GAD65 and IA-2 that bind to HLA class II molecules predisposing to or protecting
from type 1 diabetes. Diabetes October 1999 48:1937-1947; doi:10.2337/diabetes.48.10.1937
Calorie restriction increases insulin-stimulated glucose transport in skeletal muscle from IRS-1 knockout mice. Diabetes October 1999 48:1930-1936; doi:10.2337/diabetes.48.10.1930
A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes October 1999 48:2090-2095; doi:10.2337/diabetes.48.10.2090
T-cell production of an inducible interleukin-10 transgene provides limited protection from autoimmune diabetes. Diabetes October 1999 48:1948-1953; doi:10.2337/diabetes.48.10.1948
Tumor necrosis factor-alpha-238 and -308 polymorphisms do not associated with traits related to obesity and insulin resistance.
Diabetes October 1999 48:2096-2098; doi:10.2337/diabetes.48.10.2096
Evidence for a functional role of the cholecystokinin-B/gastrin receptor in the human fetal and adult pancreas. Diabetes October 1999 48:2015-2021; doi:10.2337/diabetes.48.10.2015
Evidence for a functional role of the cholecystokinin-B/gastrin receptor in the human fetal and adult pancreas. Diabetes October 1999 48:2015-2021; doi:10.2337/diabetes.48.10.2015
Metformin but not glyburide prevents high glucose-induced abnormalities in relaxation and intracellular Ca2+ transients in
adult rat ventricular myocytes. Diabetes October 1999 48:2059-2065; doi:10.2337/diabetes.48.10.2059
Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes October 1999 48:1979-1986; doi:10.2337/diabetes.48.10.1979
Metformin but not glyburide prevents high glucose-induced abnormalities in relaxation and intracellular Ca2+ transients in
adult rat ventricular myocytes. Diabetes October 1999 48:2059-2065; doi:10.2337/diabetes.48.10.2059
Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes October 1999 48:1979-1986; doi:10.2337/diabetes.48.10.1979
Evidence for a functional role of the cholecystokinin-B/gastrin receptor in the human fetal and adult pancreas. Diabetes October 1999 48:2015-2021; doi:10.2337/diabetes.48.10.2015
Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes October 1999 48:1899-1906; doi:10.2337/diabetes.48.10.1899
Calorie restriction increases insulin-stimulated glucose transport in skeletal muscle from IRS-1 knockout mice. Diabetes October 1999 48:1930-1936; doi:10.2337/diabetes.48.10.1930
Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes October 1999 48:2028-2033; doi:10.2337/diabetes.48.10.2028
Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal
islet transplantation? Diabetes October 1999 48:1907-1914; doi:10.2337/diabetes.48.10.1907
Evidence for a functional role of the cholecystokinin-B/gastrin receptor in the human fetal and adult pancreas. Diabetes October 1999 48:2015-2021; doi:10.2337/diabetes.48.10.2015
Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes October 1999 48:1979-1986; doi:10.2337/diabetes.48.10.1979
Evidence for a functional role of the cholecystokinin-B/gastrin receptor in the human fetal and adult pancreas. Diabetes October 1999 48:2015-2021; doi:10.2337/diabetes.48.10.2015
Two novel immortal pancreatic beta-cell lines expressing and secreting human islet amyloid polypeptide do not spontaneously
develop islet amyloid. Diabetes October 1999 48:1962-1970; doi:10.2337/diabetes.48.10.1962
Calorie restriction increases insulin-stimulated glucose transport in skeletal muscle from IRS-1 knockout mice. Diabetes October 1999 48:1930-1936; doi:10.2337/diabetes.48.10.1930
Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes October 1999 48:1979-1986; doi:10.2337/diabetes.48.10.1979
In vivo prevention of hyperglycemia also prevents glucotoxic effects on PDX-1 and insulin gene expression. Diabetes October 1999 48:1995-2000; doi:10.2337/diabetes.48.10.1995
Evidence for a functional role of the cholecystokinin-B/gastrin receptor in the human fetal and adult pancreas. Diabetes October 1999 48:2015-2021; doi:10.2337/diabetes.48.10.2015
Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity. Diabetes October 1999 48:2001-2006; doi:10.2337/diabetes.48.10.2001
Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal
islet transplantation? Diabetes October 1999 48:1907-1914; doi:10.2337/diabetes.48.10.1907
Evidence for a functional role of the cholecystokinin-B/gastrin receptor in the human fetal and adult pancreas. Diabetes October 1999 48:2015-2021; doi:10.2337/diabetes.48.10.2015
T-cell production of an inducible interleukin-10 transgene provides limited protection from autoimmune diabetes. Diabetes October 1999 48:1948-1953; doi:10.2337/diabetes.48.10.1948
A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes October 1999 48:2090-2095; doi:10.2337/diabetes.48.10.2090
Identification of peptides from autoantigens GAD65 and IA-2 that bind to HLA class II molecules predisposing to or protecting
from type 1 diabetes. Diabetes October 1999 48:1937-1947; doi:10.2337/diabetes.48.10.1937
In vivo prevention of hyperglycemia also prevents glucotoxic effects on PDX-1 and insulin gene expression. Diabetes October 1999 48:1995-2000; doi:10.2337/diabetes.48.10.1995
No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. Diabetes October 1999 48:1915-1921; doi:10.2337/diabetes.48.10.1915
Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes October 1999 48:2028-2033; doi:10.2337/diabetes.48.10.2028
Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes October 1999 48:1979-1986; doi:10.2337/diabetes.48.10.1979
Rapid increase in circulating leptin in ventromedial hypothalamus-lesioned rats: role of hyperinsulinemia and implication
for upregulation mechanism. Diabetes October 1999 48:2034-2038; doi:10.2337/diabetes.48.10.2034
No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. Diabetes October 1999 48:1915-1921; doi:10.2337/diabetes.48.10.1915
A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes October 1999 48:2090-2095; doi:10.2337/diabetes.48.10.2090
Two novel immortal pancreatic beta-cell lines expressing and secreting human islet amyloid polypeptide do not spontaneously
develop islet amyloid. Diabetes October 1999 48:1962-1970; doi:10.2337/diabetes.48.10.1962
In vivo prevention of hyperglycemia also prevents glucotoxic effects on PDX-1 and insulin gene expression. Diabetes October 1999 48:1995-2000; doi:10.2337/diabetes.48.10.1995
A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes October 1999 48:2090-2095; doi:10.2337/diabetes.48.10.2090
Rapid increase in circulating leptin in ventromedial hypothalamus-lesioned rats: role of hyperinsulinemia and implication
for upregulation mechanism. Diabetes October 1999 48:2034-2038; doi:10.2337/diabetes.48.10.2034
Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity. Diabetes October 1999 48:2001-2006; doi:10.2337/diabetes.48.10.2001
Identification of peptides from autoantigens GAD65 and IA-2 that bind to HLA class II molecules predisposing to or protecting
from type 1 diabetes. Diabetes October 1999 48:1937-1947; doi:10.2337/diabetes.48.10.1937
Rapid increase in circulating leptin in ventromedial hypothalamus-lesioned rats: role of hyperinsulinemia and implication
for upregulation mechanism. Diabetes October 1999 48:2034-2038; doi:10.2337/diabetes.48.10.2034
Calorie restriction increases insulin-stimulated glucose transport in skeletal muscle from IRS-1 knockout mice. Diabetes October 1999 48:1930-1936; doi:10.2337/diabetes.48.10.1930
Two novel immortal pancreatic beta-cell lines expressing and secreting human islet amyloid polypeptide do not spontaneously
develop islet amyloid. Diabetes October 1999 48:1962-1970; doi:10.2337/diabetes.48.10.1962
A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes October 1999 48:2090-2095; doi:10.2337/diabetes.48.10.2090
Rapid increase in circulating leptin in ventromedial hypothalamus-lesioned rats: role of hyperinsulinemia and implication
for upregulation mechanism. Diabetes October 1999 48:2034-2038; doi:10.2337/diabetes.48.10.2034
Low phagocytic activity of resident peritoneal macrophages in diabetic mice: relevance to the formation of advanced glycation
end products. Diabetes October 1999 48:2074-2082; doi:10.2337/diabetes.48.10.2074
A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes October 1999 48:2090-2095; doi:10.2337/diabetes.48.10.2090
A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes October 1999 48:2090-2095; doi:10.2337/diabetes.48.10.2090
Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes October 1999 48:2028-2033; doi:10.2337/diabetes.48.10.2028
Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity. Diabetes October 1999 48:2001-2006; doi:10.2337/diabetes.48.10.2001
Alpha-lipoic acid: effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy.
Diabetes October 1999 48:2045-2051; doi:10.2337/diabetes.48.10.2045
No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. Diabetes October 1999 48:1915-1921; doi:10.2337/diabetes.48.10.1915
A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes October 1999 48:2090-2095; doi:10.2337/diabetes.48.10.2090
Low phagocytic activity of resident peritoneal macrophages in diabetic mice: relevance to the formation of advanced glycation
end products. Diabetes October 1999 48:2074-2082; doi:10.2337/diabetes.48.10.2074
Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal
islet transplantation? Diabetes October 1999 48:1907-1914; doi:10.2337/diabetes.48.10.1907
Low phagocytic activity of resident peritoneal macrophages in diabetic mice: relevance to the formation of advanced glycation
end products. Diabetes October 1999 48:2074-2082; doi:10.2337/diabetes.48.10.2074
Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal
islet transplantation? Diabetes October 1999 48:1907-1914; doi:10.2337/diabetes.48.10.1907
Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes October 1999 48:2066-2073; doi:10.2337/diabetes.48.10.2066
Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia.
Diabetes October 1999 48:2022-2027; doi:10.2337/diabetes.48.10.2022
Low phagocytic activity of resident peritoneal macrophages in diabetic mice: relevance to the formation of advanced glycation
end products. Diabetes October 1999 48:2074-2082; doi:10.2337/diabetes.48.10.2074
T-cell production of an inducible interleukin-10 transgene provides limited protection from autoimmune diabetes. Diabetes October 1999 48:1948-1953; doi:10.2337/diabetes.48.10.1948
Alpha-lipoic acid: effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy.
Diabetes October 1999 48:2045-2051; doi:10.2337/diabetes.48.10.2045
Mechanisms of glucose hypersensitivity in beta-cells from normoglycemic, partially pancreatectomized mice. Diabetes October 1999 48:1954-1961; doi:10.2337/diabetes.48.10.1954
Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes October 1999 48:2028-2033; doi:10.2337/diabetes.48.10.2028
Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes October 1999 48:2028-2033; doi:10.2337/diabetes.48.10.2028
Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity. Diabetes October 1999 48:2001-2006; doi:10.2337/diabetes.48.10.2001
Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity. Diabetes October 1999 48:2001-2006; doi:10.2337/diabetes.48.10.2001
Rapid increase in circulating leptin in ventromedial hypothalamus-lesioned rats: role of hyperinsulinemia and implication
for upregulation mechanism. Diabetes October 1999 48:2034-2038; doi:10.2337/diabetes.48.10.2034
A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes October 1999 48:2090-2095; doi:10.2337/diabetes.48.10.2090
Low phagocytic activity of resident peritoneal macrophages in diabetic mice: relevance to the formation of advanced glycation
end products. Diabetes October 1999 48:2074-2082; doi:10.2337/diabetes.48.10.2074
Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity. Diabetes October 1999 48:2001-2006; doi:10.2337/diabetes.48.10.2001
A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes October 1999 48:2090-2095; doi:10.2337/diabetes.48.10.2090
Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes October 1999 48:1979-1986; doi:10.2337/diabetes.48.10.1979
Mechanisms of glucose hypersensitivity in beta-cells from normoglycemic, partially pancreatectomized mice. Diabetes October 1999 48:1954-1961; doi:10.2337/diabetes.48.10.1954
Evidence for a functional role of the cholecystokinin-B/gastrin receptor in the human fetal and adult pancreas. Diabetes October 1999 48:2015-2021; doi:10.2337/diabetes.48.10.2015
Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity. Diabetes October 1999 48:2001-2006; doi:10.2337/diabetes.48.10.2001
Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity. Diabetes October 1999 48:2001-2006; doi:10.2337/diabetes.48.10.2001
A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes October 1999 48:2090-2095; doi:10.2337/diabetes.48.10.2090
Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes October 1999 48:2028-2033; doi:10.2337/diabetes.48.10.2028
A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes October 1999 48:2090-2095; doi:10.2337/diabetes.48.10.2090
A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes October 1999 48:2090-2095; doi:10.2337/diabetes.48.10.2090
Rapid increase in circulating leptin in ventromedial hypothalamus-lesioned rats: role of hyperinsulinemia and implication
for upregulation mechanism. Diabetes October 1999 48:2034-2038; doi:10.2337/diabetes.48.10.2034
A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes October 1999 48:2090-2095; doi:10.2337/diabetes.48.10.2090
T-cell production of an inducible interleukin-10 transgene provides limited protection from autoimmune diabetes. Diabetes October 1999 48:1948-1953; doi:10.2337/diabetes.48.10.1948
Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia.
Diabetes October 1999 48:2022-2027; doi:10.2337/diabetes.48.10.2022
Alpha-lipoic acid: effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy.
Diabetes October 1999 48:2045-2051; doi:10.2337/diabetes.48.10.2045
Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal
islet transplantation? Diabetes October 1999 48:1907-1914; doi:10.2337/diabetes.48.10.1907
Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes October 1999 48:2028-2033; doi:10.2337/diabetes.48.10.2028
Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia.
Diabetes October 1999 48:2022-2027; doi:10.2337/diabetes.48.10.2022
Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes October 1999 48:2028-2033; doi:10.2337/diabetes.48.10.2028
Rapid increase in circulating leptin in ventromedial hypothalamus-lesioned rats: role of hyperinsulinemia and implication
for upregulation mechanism. Diabetes October 1999 48:2034-2038; doi:10.2337/diabetes.48.10.2034
Rapid increase in circulating leptin in ventromedial hypothalamus-lesioned rats: role of hyperinsulinemia and implication
for upregulation mechanism. Diabetes October 1999 48:2034-2038; doi:10.2337/diabetes.48.10.2034
In vivo prevention of hyperglycemia also prevents glucotoxic effects on PDX-1 and insulin gene expression. Diabetes October 1999 48:1995-2000; doi:10.2337/diabetes.48.10.1995
Identification of peptides from autoantigens GAD65 and IA-2 that bind to HLA class II molecules predisposing to or protecting
from type 1 diabetes. Diabetes October 1999 48:1937-1947; doi:10.2337/diabetes.48.10.1937
No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. Diabetes October 1999 48:1915-1921; doi:10.2337/diabetes.48.10.1915
T-cell production of an inducible interleukin-10 transgene provides limited protection from autoimmune diabetes. Diabetes October 1999 48:1948-1953; doi:10.2337/diabetes.48.10.1948
Mechanisms of glucose hypersensitivity in beta-cells from normoglycemic, partially pancreatectomized mice. Diabetes October 1999 48:1954-1961; doi:10.2337/diabetes.48.10.1954
No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. Diabetes October 1999 48:1915-1921; doi:10.2337/diabetes.48.10.1915
Palmitate and oleate induce the immediate-early response genes c-fos and nur-77 in the pancreatic beta-cell line INS-1. Diabetes October 1999 48:2007-2014; doi:10.2337/diabetes.48.10.2007
Mechanisms of glucose hypersensitivity in beta-cells from normoglycemic, partially pancreatectomized mice. Diabetes October 1999 48:1954-1961; doi:10.2337/diabetes.48.10.1954
Palmitate and oleate induce the immediate-early response genes c-fos and nur-77 in the pancreatic beta-cell line INS-1. Diabetes October 1999 48:2007-2014; doi:10.2337/diabetes.48.10.2007
Metformin but not glyburide prevents high glucose-induced abnormalities in relaxation and intracellular Ca2+ transients in
adult rat ventricular myocytes. Diabetes October 1999 48:2059-2065; doi:10.2337/diabetes.48.10.2059
Mechanisms of glucose hypersensitivity in beta-cells from normoglycemic, partially pancreatectomized mice. Diabetes October 1999 48:1954-1961; doi:10.2337/diabetes.48.10.1954
In vivo prevention of hyperglycemia also prevents glucotoxic effects on PDX-1 and insulin gene expression. Diabetes October 1999 48:1995-2000; doi:10.2337/diabetes.48.10.1995
Palmitate and oleate induce the immediate-early response genes c-fos and nur-77 in the pancreatic beta-cell line INS-1. Diabetes October 1999 48:2007-2014; doi:10.2337/diabetes.48.10.2007
Mechanisms of glucose hypersensitivity in beta-cells from normoglycemic, partially pancreatectomized mice. Diabetes October 1999 48:1954-1961; doi:10.2337/diabetes.48.10.1954
Evidence for a functional role of the cholecystokinin-B/gastrin receptor in the human fetal and adult pancreas. Diabetes October 1999 48:2015-2021; doi:10.2337/diabetes.48.10.2015
A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes October 1999 48:2090-2095; doi:10.2337/diabetes.48.10.2090
Tyrosine phosphorylation of specific protein kinase C isoenzymes participates in insulin stimulation of glucose transport
in primary cultures of rat skeletal muscle. Diabetes October 1999 48:1922-1929; doi:10.2337/diabetes.48.10.1922
Mechanisms of glucose hypersensitivity in beta-cells from normoglycemic, partially pancreatectomized mice. Diabetes October 1999 48:1954-1961; doi:10.2337/diabetes.48.10.1954
Evidence for a functional role of the cholecystokinin-B/gastrin receptor in the human fetal and adult pancreas. Diabetes October 1999 48:2015-2021; doi:10.2337/diabetes.48.10.2015
Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes October 1999 48:2028-2033; doi:10.2337/diabetes.48.10.2028
Alpha-lipoic acid: effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy.
Diabetes October 1999 48:2045-2051; doi:10.2337/diabetes.48.10.2045
Acute modulation of albumin microvascular leakage by advanced glycation end products in microcirculation of diabetic rats
in vivo. Diabetes October 1999 48:2052-2058; doi:10.2337/diabetes.48.10.2052
No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. Diabetes October 1999 48:1915-1921; doi:10.2337/diabetes.48.10.1915
Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes October 1999 48:1979-1986; doi:10.2337/diabetes.48.10.1979
Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes October 1999 48:1979-1986; doi:10.2337/diabetes.48.10.1979
Tumor necrosis factor-alpha-238 and -308 polymorphisms do not associated with traits related to obesity and insulin resistance.
Diabetes October 1999 48:2096-2098; doi:10.2337/diabetes.48.10.2096
Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity. Diabetes October 1999 48:2001-2006; doi:10.2337/diabetes.48.10.2001
Tyrosine phosphorylation of specific protein kinase C isoenzymes participates in insulin stimulation of glucose transport
in primary cultures of rat skeletal muscle. Diabetes October 1999 48:1922-1929; doi:10.2337/diabetes.48.10.1922
Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes October 1999 48:2066-2073; doi:10.2337/diabetes.48.10.2066
Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes October 1999 48:2066-2073; doi:10.2337/diabetes.48.10.2066
Mechanisms of glucose hypersensitivity in beta-cells from normoglycemic, partially pancreatectomized mice. Diabetes October 1999 48:1954-1961; doi:10.2337/diabetes.48.10.1954
Palmitate and oleate induce the immediate-early response genes c-fos and nur-77 in the pancreatic beta-cell line INS-1. Diabetes October 1999 48:2007-2014; doi:10.2337/diabetes.48.10.2007
Metformin but not glyburide prevents high glucose-induced abnormalities in relaxation and intracellular Ca2+ transients in
adult rat ventricular myocytes. Diabetes October 1999 48:2059-2065; doi:10.2337/diabetes.48.10.2059
Rapid increase in circulating leptin in ventromedial hypothalamus-lesioned rats: role of hyperinsulinemia and implication
for upregulation mechanism. Diabetes October 1999 48:2034-2038; doi:10.2337/diabetes.48.10.2034
Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal
islet transplantation? Diabetes October 1999 48:1907-1914; doi:10.2337/diabetes.48.10.1907
Low phagocytic activity of resident peritoneal macrophages in diabetic mice: relevance to the formation of advanced glycation
end products. Diabetes October 1999 48:2074-2082; doi:10.2337/diabetes.48.10.2074
Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes October 1999 48:2028-2033; doi:10.2337/diabetes.48.10.2028
Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity. Diabetes October 1999 48:2001-2006; doi:10.2337/diabetes.48.10.2001
In vivo prevention of hyperglycemia also prevents glucotoxic effects on PDX-1 and insulin gene expression. Diabetes October 1999 48:1995-2000; doi:10.2337/diabetes.48.10.1995
Evidence for a functional role of the cholecystokinin-B/gastrin receptor in the human fetal and adult pancreas. Diabetes October 1999 48:2015-2021; doi:10.2337/diabetes.48.10.2015
Two novel immortal pancreatic beta-cell lines expressing and secreting human islet amyloid polypeptide do not spontaneously
develop islet amyloid. Diabetes October 1999 48:1962-1970; doi:10.2337/diabetes.48.10.1962
Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia.
Diabetes October 1999 48:2022-2027; doi:10.2337/diabetes.48.10.2022
Tyrosine phosphorylation of specific protein kinase C isoenzymes participates in insulin stimulation of glucose transport
in primary cultures of rat skeletal muscle. Diabetes October 1999 48:1922-1929; doi:10.2337/diabetes.48.10.1922
Alpha-lipoic acid: effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy.
Diabetes October 1999 48:2045-2051; doi:10.2337/diabetes.48.10.2045
Rapid increase in circulating leptin in ventromedial hypothalamus-lesioned rats: role of hyperinsulinemia and implication
for upregulation mechanism. Diabetes October 1999 48:2034-2038; doi:10.2337/diabetes.48.10.2034
Low phagocytic activity of resident peritoneal macrophages in diabetic mice: relevance to the formation of advanced glycation
end products. Diabetes October 1999 48:2074-2082; doi:10.2337/diabetes.48.10.2074
Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes October 1999 48:1979-1986; doi:10.2337/diabetes.48.10.1979
Identification of peptides from autoantigens GAD65 and IA-2 that bind to HLA class II molecules predisposing to or protecting
from type 1 diabetes. Diabetes October 1999 48:1937-1947; doi:10.2337/diabetes.48.10.1937
Evidence for a functional role of the cholecystokinin-B/gastrin receptor in the human fetal and adult pancreas. Diabetes October 1999 48:2015-2021; doi:10.2337/diabetes.48.10.2015
Two novel immortal pancreatic beta-cell lines expressing and secreting human islet amyloid polypeptide do not spontaneously
develop islet amyloid. Diabetes October 1999 48:1962-1970; doi:10.2337/diabetes.48.10.1962
Acute modulation of albumin microvascular leakage by advanced glycation end products in microcirculation of diabetic rats
in vivo. Diabetes October 1999 48:2052-2058; doi:10.2337/diabetes.48.10.2052
No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. Diabetes October 1999 48:1915-1921; doi:10.2337/diabetes.48.10.1915
Identification of peptides from autoantigens GAD65 and IA-2 that bind to HLA class II molecules predisposing to or protecting
from type 1 diabetes. Diabetes October 1999 48:1937-1947; doi:10.2337/diabetes.48.10.1937
Tumor necrosis factor-alpha-238 and -308 polymorphisms do not associated with traits related to obesity and insulin resistance.
Diabetes October 1999 48:2096-2098; doi:10.2337/diabetes.48.10.2096
Acute modulation of albumin microvascular leakage by advanced glycation end products in microcirculation of diabetic rats
in vivo. Diabetes October 1999 48:2052-2058; doi:10.2337/diabetes.48.10.2052
Two novel immortal pancreatic beta-cell lines expressing and secreting human islet amyloid polypeptide do not spontaneously
develop islet amyloid. Diabetes October 1999 48:1962-1970; doi:10.2337/diabetes.48.10.1962
Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity. Diabetes October 1999 48:2001-2006; doi:10.2337/diabetes.48.10.2001
Alpha-lipoic acid: effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy.
Diabetes October 1999 48:2045-2051; doi:10.2337/diabetes.48.10.2045
A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes October 1999 48:2090-2095; doi:10.2337/diabetes.48.10.2090
Tumor necrosis factor-alpha-238 and -308 polymorphisms do not associated with traits related to obesity and insulin resistance.
Diabetes October 1999 48:2096-2098; doi:10.2337/diabetes.48.10.2096
Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes October 1999 48:2028-2033; doi:10.2337/diabetes.48.10.2028
Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes October 1999 48:2028-2033; doi:10.2337/diabetes.48.10.2028
Alpha-lipoic acid: effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy.
Diabetes October 1999 48:2045-2051; doi:10.2337/diabetes.48.10.2045